#United States #UCB #Pleasanton #Pharmacovigilance #Veeva

UCB Enhances Pharmacovigilance with Veeva Safety Suite

In a groundbreaking move, UCB has announced its decision to unify its global pharmacovigilance operations through the implementation of the Veeva Safety Suite. This innovative step aims to maximize operational efficiency, streamline processes, and enhance safety oversight in the pharmaceutical realm.

Pharmacovigilance is crucial in ensuring the safety of medicines post-marketing, and UCB's choice reflects a forward-thinking approach in adapting to the constantly evolving demands within healthcare.

What Does This Mean for UCB?

Jonas Maselis, UCB's head of digital technology in patient safety, expressed, “Transitioning our teams onto the Veeva Safety Suite forms a core part of UCB's safety transformation. This initiative will streamline both global and local workflows, creating a single source of truth for safety data.” This unification is particularly significant as the pharmaceutical industry increasingly shuns fragmented systems in favor of integrated platforms that elevate data integrity and accessibility.

UCB's new operational framework will revolve around the Veeva Safety Suite, which facilitates end-to-end management of safety operations. This will include optimizing the intake, processing, and submission of adverse event reports while ensuring timely communication with regulatory bodies. Additionally, leveraging Veeva SafetyDocs will help manage safety-related documents efficiently, while the Veeva Safety Workbench will enable advanced analytics for rapid reporting.

The Benefits of a Unified Platform

With Veeva Safety Signal, UCB will automate signal detection, ensuring enhanced visibility and coordination across its operational environment. The integration promises not only improved compliance with global safety standards but also robust automation that contributes to the prompt delivery of safe pharmaceuticals to patients. According to John Lawrie, Vice President of Veeva Safety, UCB is establishing a strong foundation powered by their suite to standardize its global pharmacovigilance approach.

Looking Ahead

The shift demonstrates UCB’s commitment to embracing technological advancements that simplify operations while maintaining the highest safety standards. As the landscape of drug safety management grow increasingly complex, the ability to harness technology will be imperative for pharmaceutical companies. UCB’s partnership with Veeva signifies a critical step toward future-proofing its safety management.

As UCB embarks on this new journey, the integration with Veeva Safety Suite not only underscores its dedication to patient safety but also enables the company to manage safety data effectively and with greater speed. The ultimate goal is straightforward: ensuring that every medicine provided to patients is safe and effective.

This collaboration showcases the potential of technology in facilitating better health outcomes. The shift to a unified, efficient, and automated system marks a promising direction for UCB as it navigates the complexities of modern pharmaceutical practices. From speeding up case processing to ensuring rigorous oversight, the future looks bright for UCB underpinned by its strategic adoption of Veeva Safety Suite.